Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database.
Xiangzhong XueJingjing QianPublished in: Expert opinion on drug safety (2024)
Findings call for large, longitudinal studies to examine causality of certain AEs with rituximab-pvvr and bevacizumab biosimilars.
Keyphrases
- monoclonal antibody
- adverse drug
- drug administration
- papillary thyroid
- diffuse large b cell lymphoma
- electronic health record
- squamous cell
- emergency department
- cross sectional
- metastatic colorectal cancer
- case control
- childhood cancer
- lymph node metastasis
- drug induced
- chronic lymphocytic leukemia
- hodgkin lymphoma
- squamous cell carcinoma
- human health